Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low to Intermediate-1 MDS”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00542828
What this trial is testing

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Genzyme, a Sanofi Company 16
Not applicableStudy completedNCT02378701
What this trial is testing

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 102
Testing effectiveness (Phase 2)Ended earlyNCT01222195
What this trial is testing

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT01497145
What this trial is testing

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

Who this might be right for
MDS
Kyowa Kirin Co., Ltd. 45
Testing effectiveness (Phase 2)Study completedNCT03337451
What this trial is testing

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 14
Testing effectiveness (Phase 2)Looking for participantsNCT03886662
What this trial is testing

LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
Lixte Biotechnology Holdings, Inc. 47
Testing effectiveness (Phase 2)Study completedNCT01736683
What this trial is testing

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
AnemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more
Merck Sharp & Dohme LLC 74
Large-scale testing (Phase 3)Study completedNCT02175277
What this trial is testing

Darbepoetin Alfa MDS Companion Protocol

Who this might be right for
Myelodysplastic Syndrome (MDS)
Amgen 9
Testing effectiveness (Phase 2)WithdrawnNCT00446602
What this trial is testing

Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Testing effectiveness (Phase 2)Ended earlyNCT01513317
What this trial is testing

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Janssen Research & Development, LLC 76
Testing effectiveness (Phase 2)Study completedNCT00303472
What this trial is testing

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
ThrombocytopeniaMDSMyelodysplastic Syndromes+1 more
Amgen 72
Testing effectiveness (Phase 2)Study completedNCT01584531
What this trial is testing

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromeMDSTrisomy 8
Traws Pharma, Inc. 82
Testing effectiveness (Phase 2)Study completedNCT01904682
What this trial is testing

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Who this might be right for
Myelodysplastic Syndromes
Traws Pharma, Inc. 45
Testing effectiveness (Phase 2)Study completedNCT00418665
What this trial is testing

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Who this might be right for
Myelodysplastic SyndromesThrombocytopenia
Amgen 39